Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Old Dominion Freight Line Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Old Dominion Freight Line Inc trades at $216.52 (market cap $44.82B). The key difference: Old Dominion Freight Line Inc is far larger — about 10× ACADIA Pharmaceuticals Inc.'s market cap, and Old Dominion Freight Line Inc pays a 0.54% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ODFL | |
|---|---|---|
Market Cap | $4.49B | $44.82B |
Sector | Health | Industrials |
52-Week High | $28.06 | $248.73 |
52-Week Low | $20.06 | $126.29 |
Enterprise Value | $3.69B | $44.58B |
Dividend Yield | — | 0.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ODFL trades at $215.51, down 0.98% today, with technical indicators showing a bearish trend near support at $214. The company maintains strong fundamentals with a Q1 2026 EPS beat of $1.14 versus $1.05 expected, though revenue declined to $5.5B in 2025. Valuation remains elevated with a P/E of 45.18 and P/S of 8.35, while profitability metrics like ROE of 23.33% and net margin of 18.46% highlight operational efficiency.
The outlook is mixed: analyst consensus targets $230.69 with 33% buy ratings, but near-term risks include Amazon's LTL expansion (Barron's, June 10, 2026) and high valuation concerns. Cash flow stability and debt-free balance sheet support long-term potential, though investors face headwinds from freight market volatility and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
